Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020
June 30, 2020 at 06:07 am
Share
Rasna Therapeutics, Inc. announced earnings results for the second quarter ended March 31, 2020. For the second quarter, the company announced operating loss was USD 181,580 compared to USD 263,291 a year ago. Net loss was USD 190,973 compared to USD 265,361 a year ago. For the half year, operating loss was USD 330,861 compared to USD 662,618 a year ago. Net loss was USD 349,015 compared to USD 666,664 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
ACTAVIA LIFE SCIENCES, INC. 
